Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (41-50 of 198) with videos related to

Pageof 20
Sort By:
European Urology|December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialNicholas D James, Armelle Caty, Michael Borre, et al.
BMJ Oncology|January 31, 2025
Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPathHarriet Paige Mintz, Amandeep Raj Singh Dosanjh, Helen Parsons, et al.
European Urology Focus|January 12, 2020
High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and FistulaeAmandeep Dosanjh, Philip Harvey, Simon Baldwin, et al.
Future Oncology (London, England)|July 24, 2014
Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-GuérinXiaoxuan Liu, Alexander C Dowell, Prashant Patel, et al.
BJU International|June 9, 2017
Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisationMehran Afshar, Henry Goodfellow, Francesca Jackson-Spence, et al.
Oncology Reports|April 8, 2004
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladderSyed A Hussain, Daniel H Palmer, Raji Ganesan, et al.
BJU International|September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trialNicholas D James, Armelle Caty, Heather Payne, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 15, 2026
Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programmeYa-Nan Dai, Benjamin Tura, Evan Yi-Wen Yu, et al.
Future Oncology (London, England)|February 17, 2016
The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic targetAntonio D Bardoli, Mehran Afshar, Richard Viney, et al.
Pilot and Feasibility Studies|December 9, 2020
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trialHarriet P Mintz, Amandeep Dosanjh, Helen M Parsons, et al.
Pageof 20

Showing results (41-50 of 198) with videos related to

Sort By:
Pageof 20
European Urology|December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialNicholas D James, Armelle Caty, Michael Borre, et al.
BMJ Oncology|January 31, 2025
Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPathHarriet Paige Mintz, Amandeep Raj Singh Dosanjh, Helen Parsons, et al.
European Urology Focus|January 12, 2020
High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and FistulaeAmandeep Dosanjh, Philip Harvey, Simon Baldwin, et al.
Future Oncology (London, England)|July 24, 2014
Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-GuérinXiaoxuan Liu, Alexander C Dowell, Prashant Patel, et al.
BJU International|June 9, 2017
Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisationMehran Afshar, Henry Goodfellow, Francesca Jackson-Spence, et al.
Oncology Reports|April 8, 2004
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladderSyed A Hussain, Daniel H Palmer, Raji Ganesan, et al.
BJU International|September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trialNicholas D James, Armelle Caty, Heather Payne, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 15, 2026
Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programmeYa-Nan Dai, Benjamin Tura, Evan Yi-Wen Yu, et al.
Future Oncology (London, England)|February 17, 2016
The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic targetAntonio D Bardoli, Mehran Afshar, Richard Viney, et al.
Pilot and Feasibility Studies|December 9, 2020
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trialHarriet P Mintz, Amandeep Dosanjh, Helen M Parsons, et al.
Pageof 20